







































APC = adenomatous polyposis coli; GSK-3β = glycogen synthase kinase-3β; Lef1 = lymphoid enhancer factor-1; LRP = low density lipoprotein
receptor-related protein; MMTV = mouse mammary tumor virus; Tcf = T-cell factor.
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Introduction
The discovery of Wnt1 as a mammary oncogene in the
early 1980s was, in one sense, the culmination of many
years of research on mouse models of breast cancer [1,2].
The main causative agent of those tumors was the mouse
mammary tumor virus (MMTV). Although no equivalent
viral etiology has been demonstrated for breast cancer in
humans, studies of the MMTV model were fueled by the
expectation that the underlying molecular mechanisms of
tumorigenesis would have similarities with those in human
breast cancer. Has the Wnt1 paradigm fulfilled its promise
in terms of relevance to the human disease? While the
molecular genetic similarities between the murine and
human breast cancers are not as simple as once envi-
sioned, there is growing evidence that Wnt proteins
and/or components of their signaling pathway may indeed
be of widespread significance for human breast cancer.
Wnt1 in mouse mammary tumors
The early work of Nusse and Varmus showed that MMTV
acts as an insertional mutagen in mouse mammary tissue
and that, in many MMTV-induced tumors, integration of
proviral DNA results in transcriptional activation of the
gene we now know as Wnt1 [3]. The consequences of
ectopic activation of Wnt1 in the mammary gland were
subsequently recapitulated experimentally in transgenic
mice. This confirmed the oncogenic potential of Wnt1
since the animals were predisposed to mammary tumors,
albeit after a long latency [3,4]. Wnt1 expression was also
sufficient to promote premature ductal branching and lob-
uloalveolar hyperplasia, a state of differentiation similar to
that normally observed during pregnancy. Although sur-
prising in the light of dogmas that inversely correlate cell
proliferation with terminal differentiation, these data were
consistent with prior evidence that MMTV-induced tumors
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could arise from hyperplastic alveolar nodules [5]. The
oncogenic potential of MMTV thus became largely explain-
able through the ability of the virus to activate Wnt1 or a
handful of alternative proto-oncogenes [6].
From mouse to human: no simple step
If aberrant activation of Wnt1 expression in the mouse can
promote mammary tumors, what about human WNT1 in
breast cancer? Once the human homolog was cloned,
several laboratories asked whether WNT1 transcripts were
detectable in human breast carcinomas. Although few of
these data have been published, the answer appears to
have been a resounding ‘no’ [7]. Assisted by the wisdom of
hindsight, however, we can now see that the initial ques-
tions about WNT1 expression in human breast cancer
were overly simplistic in at least two ways. First, there is a
family of WNT genes, several of which may have the same
consequences as Wnt1 if overexpressed in human cancer.
Second, the real question should be a broader one: is
there aberrant activation of the Wnt signaling pathway in
human breast cancer, whether through ligand overexpres-
sion or mutation of downstream cellular components?
Redundancy in the family
Wnt1 encodes a cysteine-rich secreted glycoprotein that
acts as an extracellular signaling factor. The gene belongs
to a family of 19 Wnt genes that encode strikingly similar
proteins, and these are now recognized as one of the most
important families of signaling molecules that regulate devel-
opment [8]. Wnt proteins influence a wide range of tissues
and affect processes such as cell fate determination, cell
growth, cell death, and differentiation. A variety of in vivo
and cell culture assays have demonstrated functional redun-
dancy among Wnt family members. For example, Wnt1
achieves the same effects as Wnt2, Wnt3a, Wnt4, Wnt7a,
and Wnt7b in an in vitro nephrogenesis assay [9,10], while
the ability of Wnt1 to cause morphological transformation of
the mammary cell line C57MG is shared by Wnt2, Wnt3,
Wnt3a, Wnt7a, and Wnt11 [11,12]. Studies of MMTV have
also pointed to redundancy in the oncogenic potential of
Wnt genes in vivo: in tumors with lack activation of Wnt1,
there can instead be insertional activation of Wnt3 or
Wnt10b [12,13].
It is notable that several members of the Wnt gene family,
unlike Wnt1 itself, are normally expressed in the develop-
ing mammary gland. These include Wnt2, Wnt4, Wnt5a,
Wnt5b,  Wnt6,  Wnt7b, and Wnt10b [12]. The dynamic
expression patterns of these Wnt genes during adoles-
cence, pregnancy, and lactation strongly suggest that they
function to regulate growth and differentiation of the gland
[14,15]. This notion is supported by the delayed side-
branching of mammary ducts observed in the absence of
Wnt4 and by the premature ductal branching and alveolar
development that results from ectopic expression of Wnt1
or Wnt10b [4,13,16].
Collectively, the data already presented support the idea
that deregulated expression of any one of several WNT
proteins in human breast tissue could potentially pheno-
copy some of the consequences of Wnt1 activation in
mice. When the net is cast that wide, there is evidence
consistent with this possibility in breast cancer. Although
systematic studies of all 19 WNT genes have not been
performed, there have been reports of overexpression of
WNT2, WNT4, WNT5A, WNT7B, WNT10B, and WNT13
in a certain proportion of breast tumors [12,17–20].
Admittedly there are problems in interpreting such data,
one of which is the difficulty in normalizing tissue RNA
samples for variable epithelial/stromal contribution. In the
case of WNT2, however, the relevant cell types have been
investigated by in situ hybridization. With caveats regard-
ing limited sample numbers, these studies imply that
WNT2 is normally expressed only in stromal tissue of the
breast, while in carcinomas it can be found in both the
epithelium and the stroma [18]. The notion of a switch
from a paracrine to an autocrine mechanism, making the
tumor cells autonomous for Wnt signaling, is one that
merits further evaluation.
Mutation of the Wnt pathway: a paradigm in
many human cancers
Even in circumstances where there is clear overexpression
of WNT genes in breast cancer, the case for their func-
tional significance is difficult to prove in the absence of
tumor-specific mutations or DNA rearrangements that acti-
vate WNT expression. Moreover, precedents from other
signaling pathways would suggest that oncogenic muta-
tions leading to constitutive signaling in cancer cells are
more likely to be found in genes encoding receptors or
downstream signaling components than in those encoding
the ligands themselves. In recent years, the Wnt signaling
pathway has become a paradigm of this principle.
A framework view of the canonical Wnt signaling pathway
is shown in Figure 1. Cell surface receptors for Wnt pro-
teins appear to be composed of at least two components:
a seven transmembrane domain protein of the Frizzled
family, and one of the low density lipoprotein receptor-
related proteins LRP5 or LRP6 [8,21–23]. Intracellular
signaling proceeds via the proteins Axin and Dishevelled.
A key downstream component of the pathway is β-catenin,
a protein with dual functions in cell adhesion and tran-
scriptional regulation. In the absence of Wnt signals, the
cytosolic pool of β-catenin is continuously degraded as a
result of its phosphorylation by glycogen synthase kinase-
3β (GSK-3β) and subsequent ubiquitination. This phos-
phorylation occurs within a multi-protein complex that
requires Axin and APC as participants. In response to Wnt
signals, the ability of GSK-3β to phosphorylate β-catenin
is inhibited. This leads to stabilization of β-catenin in the
cytosol, and its subsequent translocation to the nucleus.







































scription factors of the T-cell factor (Tcf)/lymphoid
enhancer factor-1 (Lef1) family and regulates expression
of specific target genes. The precise targets may vary
between cell types, but in some cases can include the
oncogenes c-myc and cyclin D1 [21].
Several components of the Wnt signaling pathway have
now been identified as oncogenes or tumor suppressors
(showing gain-of-function or loss-of-function mutations,
respectively) in human cancers, as shown in Figure 1. This
is most evident in colon cancer, in which 85% of tumors
have loss-of-function mutations in APC, an essential com-
ponent of the machinery that destabilizes β-catenin [21].
As with continuous Wnt stimulation, APC mutations result
in elevated β-catenin protein levels and subsequent β-
catenin-Tcf transcriptional activity. Similar signaling conse-
quences can result from mutational loss of AXIN1, as seen
in hepatocellular carcinomas [24]. Oncogenic mutations in
β-catenin itself, affecting the phosphorylation sites and
resulting in a constitutively stable protein, have recently
been detected in a remarkable variety of human cancers.
These include colorectal tumors, medulloblastomas,
hepatoblastomas, hepatocellular carcinomas, pilomatrico-
mas, endometrial, prostatic, and thyroid carcinomas, and
Wilms’ tumors [21]. These data collectively imply that acti-
vation of the Wnt signaling pathway, by one means or
another, is one of the most common signaling abnormali-
ties known in human cancer.
Evaluating the evidence in breast cancer
In addition to the oncogenic effects of Wnt genes in
mouse mammary cancer, there is further evidence that
activation of the canonical Wnt signaling pathway pro-
motes tumorigenesis in mouse mammary tissues. For
example, certain mouse strains carrying a germline trunca-
tion mutation in Apc show enhanced sensitivity to carcino-
gen-induced mammary tumors [25], while transgenic
animals expressing stabilized β-catenin in the mammary
gland develop carcinomas [26]. In view of these observa-
tions in mouse models systems, together with the wide-
spread occurrence of mutations that activate Wnt
signaling in human cancers of other tissues, it is particu-
larly surprising that equivalent mutations have generally
not been detected in human breast cancers. Several labo-
ratories have sought evidence for mutations in β-catenin,
APC, or AXIN in breast cancer, as seen in other cancers,
but few if any have been found [27–29]. The most numer-
ous identified thus far are APC mutations reported in 18%
of breast cancers in a study using a yeast-based detection
assay [30]. However, several of these mutations were
located downstream of the cluster region for APC trunca-
tions associated with constitutive Wnt/β-catenin signaling
in colon cancer, and the status of the remaining APC allele
in the tumors was uncertain [30]. Thus, where variants or
mutations in Wnt pathway components have been found in
breast cancer, it is not clear that they affect β-catenin levels
or signaling [30,31]. In contrast, elevated β-catenin-Tcf
transcriptional activity has been observed in certain breast
cancer cell lines [32], and nuclear or cytoplasmic staining
of  β-catenin has been reported in as many as 60% of
human breast cancer specimens in a recent study [32].
Most importantly, this staining pattern is an independent
marker that correlates with poor prognosis [32].
In other tissues and other organisms, the appearance of β-
catenin in the nucleus is typically considered to be a hall-
mark of activation of Wnt/β-catenin signaling. How then
can this be reconciled with the paucity of evidence for
Wnt pathway mutations in breast cancer? There are
several possible explanations. First, there might be tissue-
specific use of functionally redundant proteins. For
example, while Axin and APC are essential components of
Available online http://breast-cancer-research.com/content/3/6/351
Figure 1
Simplified diagram of the canonical Wnt/β-catenin signaling pathway.
Wnt proteins bind to receptors thought to be composed of a Frizzled
protein and either of the low density lipoprotein receptor-related
proteins LRP5 or LRP6. Signaling via Dishevelled and/or Axin then
results in inactivation of a multiprotein complex that normally renders β-
catenin unstable. This complex (shown by a dotted rectangle) includes
Axin, APC, and glycogen synthase kinase-3β (GSK-3β). By inhibiting
this complex, Wnt signals lead to accumulation of β-catenin in the
cytosol and its entry into the nucleus. Once in the nucleus, β-catenin
binds to proteins of the T-cell factor (Tcf)/lymphoid enhancer factor-1
(Lef1) family and modulates the expression of several target genes. 
* Components of the pathway identified as oncogenes in naturally
occurring mouse or human cancers, ** components identified as tumor
suppressors.the β-catenin destruction machinery in the liver and colon,
their homologs Conductin and APC2 might be the key
players in human breast tissue. Mutational analysis of
these genes in breast cancer has not yet been reported.
Second, it is possible that, in breast cancer, Wnt signaling
is activated by mutations in components of the pathway
upstream of the Axin complex. Wnt receptors themselves
could be candidate oncogenes in this context, and
mutated forms of LRP5 and LRP6 have recently been
shown to be capable of constitutive Wnt/β-catenin signal-
ing in cell culture [22,23]. It will be interesting to see
whether comparable mutations are found in breast cancer.
Mutational analysis of Frizzled genes may be more labori-
ous because there are 10 different Frizzled family
members, but there is a possible precedent for aberrant
Frizzled expression contributing to cancer in another
tissue. Frizzled7, which is not expressed in normal epithe-
lium, was detected in 86% of poorly differentiated tumors
in an analysis of esophageal cancer [33]. Wnt signaling in
breast cancer might also be activated by other regulators
of the pathway that have not yet been identified or ana-
lyzed. Since the number of proteins known to modulate
Wnt/β-catenin signaling either positively or negatively is
growing rapidly [34], the list of candidate proto-onco-
genes or tumor suppressors will continue to expand.
Finally, it is of course possible that the pathway is not acti-
vated in a cell-autonomous manner by oncogenic muta-
tions, but that excessive expression of Wnt ligands could
account for the nuclear β-catenin staining seen in tumor
biopsies and could contribute to tumor development in
vivo. As already described, there is already preliminary evi-
dence for WNT overexpression in a number of tumors.
An Odyssey returns to its beginnings
The pathway of discovery that has now re-opened ques-
tions about Wnt signaling in breast cancer is a remarkable
one that has meandered among diverse fields of modern
biology. From the initial identification of Wnt1 as an onco-
gene responsible for MMTV-induced tumors in mice came
the surprising discovery that the homolog of Wnt1 in
Drosophila is the segment polarity gene wingless [35].
Drosophila  developmental genetics then produced a
framework of the Wingless/Wnt signaling pathway, a key
component of which was Armadillo [36]. Studies in
Xenopus then revealed that Armadillo was homologous to
the adherens junction protein β-catenin, that β-catenin
could mediate Wnt signaling events and, remarkably, that
it could enter the nucleus [37]. Jump now to hereditary
colon cancer and the identification of APC as the tumor
suppressor responsible for Familial Adenomatous Polypo-
sis [38]. Studies of this novel protein soon showed that
APC bound cytosolic β-catenin and facilitated its phos-
phorylation and destruction [39]. Oncogenic mutant forms
of  β-catenin were then discovered in colon cancer and
many other cancers, and the detection of β-catenin in the
nucleus was recognized as a characteristic feature of Wnt
pathway activation [21]. Although specific fixation and
staining methods may be required to reveal this in tissue
sections, the recent immunohistochemical data of Lin et al
[32] now bring this path back to breast cancer.
Conclusion
The relevance of Wnt1 to human breast cancer has been
in question for nearly 20 years. A remarkable set of studies
in Drosophila, Xenopus, mice, humans, and other species
has now revealed a large family of Wnt proteins and a
highly conserved pathway of intracellular signaling through
which they act. Activation of this signaling pathway by
mutation is a common feature of many human cancers.
Few mutations of this sort have so far been described in
breast cancer, but WNT proteins may be overexpressed in
tumors and recent immunohistochemical evidence implies
that components of the Wnt/β-catenin pathway are acti-
vated in up to 60% of breast carcinomas [32]. Those who
would describe a half-full glass as half-empty might argue
that the case for Wnt signaling in breast cancer is not
proven, but others would claim that the writing on the wall
is writ large. It may be just a matter of time before we
appreciate more clearly the mechanism and significance
of Wnt pathway activation in breast cancer, in which case
MMTV will have done its job and the connection between
those early mouse models and human breast cancer will
have come full circle.
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